Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews.
Ulugbek NurmatovSangeeta DhamiStefania ArasiGraham RobertsOliver PfaarAntonella MuraroIgnacio J AnsoteguiMoises CalderonCemal CingiStephen DurhamRoy Gerth van WijkSusanne HalkenEckard HamelmannPeter HellingsLars JacobsenEdward KnolDesiree Larenas-LinnemannSandra Y LinVivian MagginaHanneke Oude-ElberinkGiovanni PajnoRuby PanwankarElideanna PastorelloConstantinos PitsiosGiuseppina RotirotiFrans TimmermansOlympia TsilochristouEva-Maria VargaJamie WilkinsonAndrew WilliamsMargitta WormLuo ZhangAziz SheikhPublished in: Clinical and translational allergy (2017)
We found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients, reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and protocols studied. There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated into the published systematic reviews.
Keyphrases
- systematic review
- end stage renal disease
- electronic health record
- meta analyses
- newly diagnosed
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- big data
- healthcare
- peritoneal dialysis
- prognostic factors
- emergency department
- allergic rhinitis
- single cell
- machine learning
- physical activity
- depressive symptoms